Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Xiaomin Niu(Jinzhou Medical University), Shun Lü(Shanghai Jiao Tong University), Daizhan Zhou(Chinese Academy of Sciences), Yun Liu(Jiangnan University), Ting Wang(Jilin University), Zhiwei Chen(Fujian Medical University), Zhen Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yi Zhou(Beijing Forestry University), Ziming Li(Shanghai Jiao Tong University), Xiangyun Ye(Shanghai Chest Hospital), Yongfeng Yu(Shanghai Chest Hospital), Hong Zhang(Qingdao University), Junyi Ye(Burning Rock Biotech (China)), Xiaoling Weng(Shanghai Medical College of Fudan University), Meilin Liao(Shanghai Chest Hospital), Fatao Liu(Shanghai Jiao Tong University)
Cited by 20
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k